Lutetium Lu177 Edotreotide

Amgen has initiated two pivotal Phase 3 trials of MariTide for obesity treatment, targeting both diabetic and non-diabetic populations with a three-tiered dosing strategy.

ITM-11, a targeted radiopharmaceutical, significantly improved progression-free survival (PFS) in patients with Grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

ITM-11, a targeted radiopharmaceutical, demonstrated superior progression-free survival compared to everolimus in patients with grade 1-2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for expanded use in patients with metastatic, hormone-positive breast cancer expressing low and ultra-low levels of HER2. This significant expansion covers treatment after hormone therapy for the most prevalent breast cancer type, potentially benefiting a broader patient population.

Datroway (Dato-DXd) gains first global approval in Japan for previously treated, unresectable, or recurrent HR-positive, HER2-negative breast cancer, offering a new alternative to conventional chemotherapy.